CHiR Therapy for Elderly DLBCL Intolerant to Chemo

Inclusion criteria

：

• Age ≥ 70 years;
• ECOG score of 0-3;
• Rated as unfit or frail on the simplified geriatric assessment (sGA);
• Histologically confirmed CD20-positive diffuse large B-cell lymphoma (diagnostic criteria according to WHO 2016), excluding transformed type 2 DLBCL;
• Immunohistochemically confirmed positive expression of MYC and BCL2 (MYC ≥ 40%, BCL2 ≥ 50% by immunohistochemistry);
• Previously untreated patients;
• Cardiac, hepatic, and renal function: creatinine < 2 times the upper limit of normal (ULN); ALT (alanine aminotransferase)/AST (aspartate aminotransferase) < 2.5 ULN; total bilirubin < 2 ULN;
• At least one measurable lesion;
• Unable to tolerate standard CHOP regimen chemotherapy or unwilling to receive chemotherapy;
• Adequate understanding and voluntary signing of the informed consent form. Exclusion Criteria：

1.Patients with central nervous system involvement at the time of onset; 2.Known human immunodeficiency virus (HIV) infection; 3.Pregnant or lactating women; 4.Other tumors requiring treatment; 5.Uncontrollable active infection; 6.Active hepatitis with HBV-DNA copy number not controlled within 2*1000/mL despite antiviral treatment; 7.Inability to understand, comply with the study protocol, or sign the informed consent form.